Abstract:<p>Bleeding resulting from the application of low-molecular-weight heparins (LMWHs) may be treated with protamine sulfate, but this treatment lacks efficiency; its action against antifactor Xa activity is limited to ~60%. Moreover, protamine sulfate can cause life-threatening hypersensitivity reactions. We developed diblock heparin-binding copolymer (HBC), which can neutralize the anticoagulant activity of parenteral anticoagulants. In the present study, we explored the safety profile of HBC and its potential to reverse enoxaparin, nadroparin, dalteparin, and tinzaparin in human plasma and at in vivo conditions. HBC-LMWH complexes were characterized using zeta potential, isothermal titration calorimetry, and dynamic light scattering. The rat cardiomyocytes and human endothelial cells were used for the assessment of in vitro toxicity. Male Wistar rats were observed for up to 4 days after HBC administration for clinical evaluation, gross necropsy, and biochemistry and histopathological analysis. Rats were treated with LMWHs alone or followed by short-time intravenous infusion of HBC, and bleeding time and antifactor Xa activity were measured. HBC completely reversed antifactor Xa activity prolonged in vitro by all LMWHs with an optimal weight ratio of 2.5:1. The complexes of HBC-LMWHs were below 5 µm. We observed no effects on the viability of cardiovascular cells treated with HBC at concentrations up to 0.05 mg/ml. Single doses up to 20 mg/kg of HBC were well tolerated by rats. HBC completely reversed the effects of LMWHs on bleeding time and antifactor Xa activity in vivo after 20 minutes and retained ~80% and ~60% of reversal activity after 1 and 2 hours, respectively. Well-documented efficacy and safety of HBC both in vitro and in vivo make this polymer a promising candidate for LMWHs reversal.</p>SIGNIFICANCE STATEMENT<p>Over the last decade, there has been significant progress in developing antidotes for the reversal of anticoagulants. Until now, there has been no effective and safe treatment for patients with severe bleeding under low-molecular-weight heparin therapy. Based on our in vitro and in vivo studies, heparin-binding copolymer seems to be a promising candidate for neutralizing all clinically relevant low-molecular-weight heparins.</p>

Porous dynamic covalent polymers as promising reversal agents for heparin anticoagulants

Porous Polymers as Universal Reversal Agents for Heparin Anticoagulants through an Inclusion–Sequestration Mechanism

Correction: Evaluation of a Novel Thermosensitive Heparin-Poloxamer Hydrogel for Improving Vascular Anastomosis Quality and Safety in a Rabbit Model.

Robust, Highly Elastic and Bioactive Heparin-Mimetic Hydrogels

Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats

External Trigger Free Charge Switchable Cationic Ligands in the Design of Safe and Effective Universal Heparin Antidote

Dynamic Covalent Polymer Networks: from Old Chemistry to Modern Day Innovations

Research Progress of Low Molecular Weight Heparin

Polydopamine-heparin Complex Reinforced Antithrombotic and Antimicrobial Activities of Heparinized Hydrogels for Biomedical Applications

A heparin derivatives library constructed by chemical modification and enzymatic depolymerization for exploitation of non-anticoagulant functions

Caltrop-like Small-Molecule Antidotes That Neutralize Unfractionated Heparin and Low-Molecular-Weight Heparin in Vivo.

STUDIES OF NEW-TYPE HEPARINIZED POLYSTYRENE FILM SURFACES AND THEIR ANTITHROMBOGENICITY IN VITRO

Preparation of Low Molecular Weight Heparin Using an Ultrasound-Assisted Fenton-system

STUDY ON COVALENT IMMOBILIZATION OF HEPARIN ONTO A NEW POLYURETHANE BY ESTER BONDS

Polycarbonate Urethane Films Modified by Heparin to Enhance Hemocompatibility and Endothelialization

PCL-based and Hirudin-containing Composite Nanofibers for Prolonged Anticoagulation Effect

Immobilized Heparin and Its Anti-Coagulation Effect on Polysulfone Membrane Surface

Core–Shell Magnetic Nanoparticles of Heparin Conjugate As Recycling Anticoagulants

Heparin As a Molecular Spacer Immobilized on Microspheres to Improve Blood Compatibility in Hemoperfusion.

Development of Low Molecular Weight Heparin by H2O2/ascorbic Acid with Ultrasonic Power and Its Anti-Metastasis Property.

Heparinized anticoagulant coatings based on polyphenol-amine inspired chemistry for blood-contacting catheters